NEW LOCATION: The FH Canada Patient Network invites you to a “first-ever” Canadian public meeting: October 24, 2015

The FH Canada Patient Network invites you to a “first-ever” Canadian public meeting … all about LDL cholesterol. How does LDL-C effect people? How big of a risk is it? What really causes high cholesterol? What works and doesn’t work to control it?

Join us on October 24, 2015 at the Sheraton Gateway Hotel located at Pearson International Airport, just before the start of the Canadian Cardiovascular Congress for a documentary film screening, panel discussion with three of the top Canadian experts in “high cholesterol” and a “guided exploration” of “your personal journey” living with hypercholesterolemia.

Click here for revised final agenda

There is no cost to attend

Register here: https://www.surveymonkey.com/r/fhregistration

 

We also have a Survey that is directed to persons with high levels of LDL (“bad”) cholesterol or their caregivers A new class of drugs called PCSK9 inhibitors that include alirocumab, evolocumab, and bococizumab are used to treat high LDL  The PCSK9 inhibitors have been or will be reviewed by Canada’s Common Drug Review (CDR), to determine whether the drug should be funded by the provincial drug plans for treatment of (uncontrolled) high cholesterol.

Survey: https://www.surveymonkey.com/r/FHSurvey2